全文获取类型
收费全文 | 58027篇 |
免费 | 5763篇 |
国内免费 | 3514篇 |
专业分类
耳鼻咽喉 | 445篇 |
儿科学 | 825篇 |
妇产科学 | 571篇 |
基础医学 | 6621篇 |
口腔科学 | 1071篇 |
临床医学 | 7514篇 |
内科学 | 7717篇 |
皮肤病学 | 733篇 |
神经病学 | 2711篇 |
特种医学 | 2215篇 |
外国民族医学 | 19篇 |
外科学 | 5292篇 |
综合类 | 11045篇 |
现状与发展 | 15篇 |
一般理论 | 2篇 |
预防医学 | 4445篇 |
眼科学 | 1207篇 |
药学 | 6675篇 |
54篇 | |
中国医学 | 3851篇 |
肿瘤学 | 4276篇 |
出版年
2024年 | 80篇 |
2023年 | 796篇 |
2022年 | 1387篇 |
2021年 | 2591篇 |
2020年 | 2188篇 |
2019年 | 1787篇 |
2018年 | 1952篇 |
2017年 | 1887篇 |
2016年 | 1850篇 |
2015年 | 2834篇 |
2014年 | 3453篇 |
2013年 | 3519篇 |
2012年 | 4969篇 |
2011年 | 5392篇 |
2010年 | 3665篇 |
2009年 | 2925篇 |
2008年 | 3561篇 |
2007年 | 3474篇 |
2006年 | 3242篇 |
2005年 | 2921篇 |
2004年 | 2148篇 |
2003年 | 2038篇 |
2002年 | 1723篇 |
2001年 | 1361篇 |
2000年 | 1158篇 |
1999年 | 929篇 |
1998年 | 536篇 |
1997年 | 499篇 |
1996年 | 356篇 |
1995年 | 341篇 |
1994年 | 335篇 |
1993年 | 187篇 |
1992年 | 213篇 |
1991年 | 193篇 |
1990年 | 169篇 |
1989年 | 127篇 |
1988年 | 112篇 |
1987年 | 94篇 |
1986年 | 78篇 |
1985年 | 67篇 |
1984年 | 29篇 |
1983年 | 18篇 |
1982年 | 17篇 |
1981年 | 18篇 |
1980年 | 6篇 |
1979年 | 33篇 |
1978年 | 5篇 |
1977年 | 5篇 |
1976年 | 7篇 |
1969年 | 6篇 |
排序方式: 共有10000条查询结果,搜索用时 150 毫秒
1.
2.
3.
Lee Hee Yun Hao Zhichao Choi Eun Young 《Journal of immigrant and minority health / Center for Minority Public Health》2022,24(4):996-1004
Journal of Immigrant and Minority Health - Little attention has been paid to online health information seeking (OHIS) among immigrants residing in rural areas. This study examines the intensity of... 相似文献
4.
目的 分析重症患者营养支持期间发生再喂养综合征的危险因素,为早期识别及预防再喂养综合征提供参考。方法 检索中国知网、万方数据库、中华医学期刊全文数据库、中国生物医学文献数据库、维普网、PubMed、Embase、Cochrane Library、Elsevier关于重症患者再喂养综合征危险因素的文献,检索时间为各数据库建库至2021年12月,采用RevMan5.3进行Meta分析。结果 纳入13篇文献,包括2 519例患者,其中病例组793例,对照组1 726例;Meta分析合并效应值显示年龄(WMD=4.69)、APACHEⅡ评分(WMD=2.50)、BMI(WMD=-0.94)、白蛋白水平(OR=4.61)、前白蛋白水平(WMD=-53.46)、基线血镁水平(WMD=-0.05)、基线血钾水平(WMD=0.18)、基线血磷水平(WMD=-0.07)是重症患者发生再喂养综合征的危险因素(P<0.05,P<0.01)。结论 基于现有证据,重症患者再喂养综合征的危险因素包括年龄、APACHEⅡ评分、营养状况及电解质水平,医护人员需密切关注重症患者营养支持期间能量、蛋白质及电解... 相似文献
5.
6.
社会力量具备相应的经济基础和技术条件,对于公立互联网医院体系建设具有积极的促进作用。但是实践中仍然存在商业模式不完善、监管制度不健全等问题。基于经济学契约理论要义,提出在坚持激励与约束机制并举、平衡公私益关系的前提下,通过完善医保政策、构建互联网医疗服务价格分类管理机制来促进社会力量向医疗服务公益性目标回归,并通过构建完善的监督体制来约束部分社会力量的盲目逐利性行为。 相似文献
7.
8.
Zeyu Li Erwei Hao Rui Cao Si Lin Linghui Zou Tianyan Huang Zhengcai Du Xiaotao Hou Jiagang Deng 《中草药(英文版)》2022,14(4):479-493
Zedoary tumeric (Curcumae Rhizoma, Ezhu in Chinese) has a long history of application and has great potential in the treatment of liver cancer. The anti liver cancer effect of zedoary tumeric depends on the combined action of multiple pharmacodynamic substances. In order to clarify the specific mechanism of zedoary tumeric against liver cancer, this paper first analyzes the mechanism of its single pharmacodynamic substance against liver cancer, and then verifies the joint anti liver cancer mechanism of its "pharmacodynamic group". By searching the research on the anti hepatoma effect of active components of zedoary tumeric in recent years, we found that pharmacodynamic substances, including curcumol, zedoarondiol, curcumenol, curzerenone, curdione, curcumin, germacrone, β-elemene, can act on multi-target and multi-channel to play an anti hepatoma role. For example, curcumin can regulate miR, GLO1, CD133, VEGF, YAP, LIN28B, GPR81, HCAR-1, P53 and PI3K/Akt/mTOR, HSP70/TLR4 and NF-κB. Wnt/TGF/EMT, Nrf2/Keap1, JAK/STAT and other pathways play an anti hepatoma role. Network pharmacological analysis showed that the core targets of the "pharmacodynamic group" for anti-life cancer are AKT1, EGFR, MAPK8, etc, and the core pathways are neuroactive live receiver interaction, nitrogen metabolism, HIF-1 signaling pathway, etc. At the same time, by comparing and analyzing the relationship between the specific mechanisms of pharmacodynamic substance and "pharmacodynamic group", it is found that they have great reference significance in target, pathway, biological function, determination of core pharmacodynamic components, formation of core target protein interaction, in-depth research of single pharmacodynamic substance, increasing curative effect and so on. By analyzing the internal mechanism of zedoary tumeric pharmacodynamic substance and "pharmacodynamic group" in the treatment of liver cancer, this paper intends to provide some ideas and references for the deeper pharmacological research of zedoary tumeric and the relationship between pharmacodynamic substance and "pharmacodynamic group". 相似文献
9.
10.
Wuteng Cao Huabin Hu Jiao Li Qianyu Wu Lishuo Shi Biao Li Jie Zhou Xinhua Wang Junhong Chen Chao Wang Huaiming Wang Weihao Deng Yan Huang Yanhong Deng 《International journal of cancer. Journal international du cancer》2023,153(11):1894-1903
Neoadjuvant programmed cell death protein 1 (PD-1) blockade exhibits promising efficacy in patients with mismatch repair deficient (dMMR) colorectal cancer (CRC). However, discrepancies between radiological and histological findings have been reported in the PICC phase II trial (NCT 03926338). Therefore, we strived to discern radiological features associated with pathological complete response (pCR) based on computed tomography (CT) images. Data were obtained from the PICC trial that included 36 tumors from 34 locally advanced dMMR CRC patients, who received neoadjuvant PD-1 blockade for 3 months. Among the 36 tumors, 28 (77.8%) tumors achieved pCR. There were no statistically significant differences in tumor longitudinal diameter, the percentage change in tumor longitudinal diameter from baseline, primary tumor sidedness, clinical stage, extramural venous invasion status, intratumoral calcification, peritumoral fat infiltration, intestinal fistula and tumor necrosis between the pCR and non-pCR tumors. Otherwise, tumors with pCR had smaller posttreatment tumor maximum thickness (median: 10 mm vs 13 mm, P = .004) and higher percentage decrease in tumor maximum thickness from baseline (52.9% vs 21.6%, P = .005) compared to non-pCR tumors. Additionally, a higher proportion of the absence of vascular sign (P = .003, odds ratio [OR] = 25.870 [95% CI, 1.357-493.110]), nodular sign (P < .001, OR = 189.000 [95% CI, 10.464-3413.803]) and extramural enhancement sign (P = .003, OR = 21.667 [2.848-164.830]) was observed in tumors with pCR. In conclusion, these CT-defined radiological features may have the potential to serve as valuable tools for clinicians in identifying patients who have achieved pCR after neoadjuvant PD-1 blockade, particularly in individuals who are willing to adopt a watch-and-wait strategy. 相似文献